Royal Bank Of Canada Has Lowered Expectations for argenex (NASDAQ:ARGX) Stock Price

argenex (NASDAQ:ARGX) had its price target cut by stock analysts at Royal Bank Of Canada from $925.00 to $890.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 15.07% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research note on Wednesday, January 14th. Stifel Nicolaus increased their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Citigroup decreased their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Finally, Citizens Jmp increased their target price on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Price Performance

NASDAQ:ARGX traded up $1.88 during mid-day trading on Friday, hitting $773.41. The company’s stock had a trading volume of 278,985 shares, compared to its average volume of 390,995. The business’s fifty day moving average is $828.13 and its two-hundred day moving average is $809.87. The stock has a market cap of $47.86 billion, a price-to-earnings ratio of 33.21, a PEG ratio of 0.71 and a beta of 0.37. argenex has a 1 year low of $510.05 and a 1 year high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 29.78% and a net margin of 41.58%.The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Analysts anticipate that argenex will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in argenex by 91.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after buying an additional 4,217 shares during the last quarter. Allianz Asset Management GmbH lifted its holdings in argenex by 21.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after buying an additional 645 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of argenex by 14.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after acquiring an additional 26,343 shares in the last quarter. Alta Wealth Advisors LLC acquired a new position in shares of argenex during the 3rd quarter worth about $623,000. Finally, Fiera Capital Corp increased its holdings in shares of argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock valued at $131,030,000 after acquiring an additional 19,180 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx announced positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis, meeting the primary endpoint (p=0.012) and supporting a planned sBLA submission — a clear catalyst for future label expansion and sales growth. ADAPT OCULUS Results
• Positive Sentiment: argenx reported strong Q4 and full‑year 2025 financials: $1.32B in Q4 product net sales (beat) and ~$4.2B for the year (≈90% YoY growth), and an EPS beat ($8.02 vs. $6.05 est.) — fundamentals that validate commercial traction for VYVGART and underpin higher valuation assumptions. Q4 Earnings Release
• Positive Sentiment: Citizens Jmp and HC Wainwright raised price targets (to $944 and $940, respectively) and kept bullish ratings, signaling continued analyst confidence in upside from current levels. Analyst Raises
• Neutral Sentiment: Robert W. Baird nudged its target slightly to $867 but maintained a neutral rating — a modest endorsement but less bullish than some peers. Baird Update
• Neutral Sentiment: Guggenheim and Wells Fargo trimmed their price targets (Guggenheim to $1,120; Wells Fargo to $1,247) but kept buy/overweight stances — indicates analysts are calibrating upside after earnings while still positive on the story. Analyst Cuts
• Neutral Sentiment: Reported short‑interest data in the filings looks anomalous (values shown as 0/NaN and days‑to‑cover 0.0), so short‑interest signals are unreliable in the current reporting — treat with caution.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.